| Stereochemistry | RACEMIC |
| Molecular Formula | C11H14N2O2 |
| Molecular Weight | 206.2411 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(C(=O)NC(N)=O)C1=CC=CC=C1
InChI
InChIKey=AJOQSQHYDOFIOX-UHFFFAOYSA-N
InChI=1S/C11H14N2O2/c1-2-9(10(14)13-11(12)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H3,12,13,14,15)
| Molecular Formula | C11H14N2O2 |
| Molecular Weight | 206.2411 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Pheneturide ((brand names Benuride, Deturid, Pheneturid, Septotence, Trinuride), a decarboxylation product of phenobarbital, has been shown to be an effective drug against seizures, and in particular psychomotor seizures. It has being marketed in Europe, including in Poland, Spain, and the United Kingdom. Pheneturide is supplied in compressed tablets each containing 200 mg. of the drug. It can also be obtained in compound tablets (" trinuride ') each of which contain 200 mg. of pheneturide, 40 mg. of diphenylhydantoin, and 15 mg. of phenobarbitone. Animal experiments have shown that pheneturide protects against drug-induced and electrically induced convulsions.
